Masdeu, 2011 - Google Patents
Neuroimaging in psychiatric disordersMasdeu, 2011
View HTML- Document ID
- 8437742295941809509
- Author
- Masdeu J
- Publication year
- Publication venue
- Neurotherapeutics
External Links
Snippet
In psychiatry, neuroimaging facilitates the diagnosis of psychiatric disorders and the development of new medications. It is used to detect structural lesions causing psychosis and to differentiate depression from neurodegenerative disorders or brain tumors …
- 238000002610 neuroimaging 0 title abstract description 37
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Masdeu | Neuroimaging in psychiatric disorders | |
Parsey et al. | Lower serotonin transporter binding potential in the human brain during major depressive episodes | |
Anand et al. | Striatal dopamine transporter availability in unmedicated bipolar disorder | |
Tiger et al. | A randomized placebo-controlled PET study of ketamine´ s effect on serotonin1B receptor binding in patients with SSRI-resistant depression | |
Meyer et al. | Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C] DASB positron emission tomography study | |
Drzezga et al. | Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden | |
Yanai et al. | The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies | |
Cannon et al. | Serotonin transporter binding in bipolar disorder assessed using [11C] DASB and positron emission tomography | |
Ballard et al. | Neural correlates of suicidal ideation and its reduction in depression | |
Cervenka et al. | Associations between dopamine D2-receptor binding and cognitive performance indicate functional compartmentalization of the human striatum | |
Zubieta et al. | High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: sex differences and cognitive correlates | |
Yeh et al. | Availability of dopamine and serotonin transporters in opioid-dependent users—a two-isotope SPECT study | |
Zink et al. | Association of missense mutation in FOLH1 with decreased NAAG levels and impaired working memory circuitry and cognition | |
Mattioli et al. | Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients | |
Abou-Saleh | Neuroimaging in psychiatry: an update | |
Plavén-Sigray et al. | Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis | |
Rodríguez-Chinchilla et al. | [18 F]-DPA-714 PET as a specific in vivo marker of early microglial activation in a rat model of progressive dopaminergic degeneration | |
Tseng et al. | In vivo human brain expression of histone deacetylases in bipolar disorder | |
Boscutti et al. | PET Radioligands for imaging of the PDE10A in human: current status | |
Asai et al. | GABAA/Benzodiazepine receptor binding in patients with schizophrenia using [11C] Ro15-4513, a radioligand with relatively high affinity for α5 subunit | |
Shin et al. | The relationship between frontostriatal connectivity and striatal dopamine function in schizophrenia: An 18F-DOPA PET and Diffusion tensor imaging study in treatment responsive and resistant patients | |
Borg et al. | Contribution of non-genetic factors to dopamine and serotonin receptor availability in the adult human brain | |
Sharma et al. | SPECT neuroimaging in translational research of CNS disorders | |
Song et al. | Amphetamine-induced dopamine release and impulsivity in Parkinson’s disease | |
Viviani et al. | Effects of amisulpride on human resting cerebral perfusion |